Mr. Nils Behrndt, Deputy Head of Unit, Directorate F2 (Pharmaceuticals), DG Enterprise and Industry, European Commission has agreed to join the TOPRA Advisory Council.
TOPRA received yet another endorsement of its leading role in the global regulatory affairs industry. Mr. Nils Behrndt, Deputy Head of Unit, Directorate F2 (Pharmaceuticals), DG Enterprise and Industry, European Commission has agreed to join the TOPRA Advisory Council.
Mr. Behrndt has enjoyed an illustrious career at the European Commission, previously serving as the Acting Head of the Directorate F2. Mr. Behrndt has served the Commission since 2000 as a lawyer and advisor. Previously, he served as a lawyer and researcher for a variety of organisations and entities within Germany. He holds law degrees from Germany and the United Kingdom as well as having a Ph.D. in public administration and law.
TOPRA's President, Margareth Jorvid said, "We are delighted that Nils has joined our ranks. TOPRA will benefit immensely from his guidance and technical expertise offered through our Advisory Council."
Ms. Jorvid went onto say, "I think that this appointment really shows the maturity of our organisation and our expanding appeal worldwide, but most especially within the European Union. We are proud to have such a high-ranking official from the European Commission join TOPRA's Advisory Council."
TOPRA members are currently drawn from 52 countries.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.